News | April 25, 2007

Cardiologist Launches New Heart Supplements

April 26, 2007 — Cardiologist Lee A. Surkin, M.D., FAAC, is set to launch a new line of cardiac nutritional supplements this July. He says the new Cardiac Wellness Supplements are designed to complement, not replace, standard cardiovascular disease prevention and treatment therapies.

"Simply put, I developed Cardiac Wellness Supplements out of necessity," said Dr. Surkin. "I believe in an integrative approach to the prevention and treatment of cardiovascular disease. That means traditional medical care, exercise, and basic nutrition. As my patients became more educated, they asked me for recommendations for supplements to help improve their nutrition. I wasn't able to find the right supplements to meet their needs, so I developed my own proprietary line of products that I am now bringing to a broader market."

"Supplements are a worrisome area for many physicians because in most cases there is a real lack of solid scientific data to support safety or outcome," said Dr. Surkin. "As I looked at products available in the marketplace, I found few suitable options. And of the products I was comfortable recommending, expense was almost always an obstacle. Now, with my Wellcor Products, I can comfortably recommend products that have data to support them and are cost-effective."

Dr. Surkin utilized his training in human nutrition and cardiology to develop Cardiac Wellness Supplements, focusing on ingredients that have substantial scientific data on safety, efficacy and dosage. The product line will include five products: Wellcor Defense -- Omega 3, Wellcor Energize -- Supreme Green Tea, Wellcor Guard -- Resveratrol / Quercitin, Wellcor Strength -- CoEnzyme Q10 / Hawthorn and Wellcor Control -- Alpha-Lipoic Acid / L- Carnitine.
For more information visit www.cardiacwellness.com.

Related Content

Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals| May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals| May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals| April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals| March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals| March 28, 2017
When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly...
Overlay Init